Navigating ALK-positive Clinical Trials: Facts Timelines, and Real Expectations

On Sunday, March 29 at 7:00pm ET, Dr. Riess and Johanna Han joined ALKtALK for an educational conversation focused on ALK+ cancer clinical trials, including single-patient INDs (Investigational New Drugs)—what they are, what they are not, and what patients and care partners should realistically expect when considering this path. The discussion addressed common misconceptions, eligibility considerations, timelines, and how single-patient INDs fit within the broader clinical research landscape.

Jonathan Riess, MD, MS, is the Director of Thoracic Oncology at the UC Davis Comprehensive Cancer Center and has extensive experience caring for ALK+ patients, having served as an investigator on most ALK+ lung cancer clinical trials. He is joined by Johanna Han, MSc, CCRP, Assistant Director of the Early Phase Clinical Trials Program at UC Davis Comprehensive Cancer Center, where she oversees the operations and execution of early-phase oncology research. Johanna brings more than 10 years of experience managing a wide range of oncology research initiatives across large academic, NCI-designated comprehensive cancer centers.

Watch now to be informed and empowered by a thoughtful, data-informed conversation designed to help patients and care partners better understand complex regulatory pathways and evolving treatment options.

Whether you are newly diagnosed, exploring treatment options, or supporting someone you love, we invite you to join this important ALKtALK and stay connected to the information shaping our community.

#ALKPositive #ALKtALK #LungCancerResearch #MoreResearchMoreTime